Published in Obesity and Diabetes Week, April 25th, 2005
The company is currently assessing recent clinical developments involving other GLP-1 analogues to determine the best way to position itself competitively in the market for this new class of drugs.
The primary objective of the phase 1 study was to demonstrate the safety of TH0318 through a randomized, single-center, dose-escalation, parallel, placebo-controlled trial. The study population consisted of 36 healthy male volunteers, aged 18 to 45, divided into 6 cohorts. TH0318 was administered by subcutaneous injection...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week